Answers are grounded in this paper and cite their sources.
SUPPLEMENT — SIMULATED, NOT MEASURED — NOT BUILT. Supplement to 'Cell-Free DNA Circuits — Design Blueprint' (DOI: 10.5281/zenodo.24111600), derived from the source design 'Cell-Free DNA Circuits as the Safer Injectable' (DOI: 10.5281/zenodo.24109036). Adds the two items the blueprint lacks. (1) A costed process estimate from declared planning assumptions (market-typical ranges per process class, not quotations): oligonucleotide synthesis at USD 2.50–6.50 per base at the 1 micromole lot scale, assembly and purification class costs, quality-control assays implied by the blueprint's acceptance criteria (USD 5,050 per batch), fill/finish and cold chain — total USD 545 (low), USD 732 (mid), USD 1,043 (high) per 10 mg dose at a 100-dose reference batch, with synthesis the dominant term at 78.8% of the mid-case total and batch size and combined yield as the governing sensitivities. (2) A standalone administration-and-monitoring design at principle and parameter level: dose-preparation verification checks, the 14.5-hour working window and 4.36-hour half-life as timing anchors, clearance checkpoints (97.8% of the dose cleared in 24 hours), the 0.143% dose-arrival threshold as the monitoring readout, thresholded reporter readout against the stated healthy-cell background, and stopping rules. No sequence and no wet-lab protocol quantity. Nothing described has been built, synthesised, or tested, and no clinical use is claimed or authorised.
No takes yet. Share an insight, caveat, or question.
William Alexander Aldred (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: